These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 4025384)

  • 21. Clinical adverse effects during ceftriaxone therapy.
    Moskovitz BL
    Am J Med; 1984 Oct; 77(4C):84-8. PubMed ID: 6093526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Side effects of cephalosporins.
    Norrby SR
    Drugs; 1987; 34 Suppl 2():105-20. PubMed ID: 3319495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abnormal laboratory test values during ceftriaxone therapy.
    Oakes M; MacDonald H; Wilson D
    Am J Med; 1984 Oct; 77(4C):89-96. PubMed ID: 6093527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Moxalactam, bleeding, and renal insufficiency.
    D'Elia JA; Kaldany A; Miller DG; Yoburn DC; Kaye WA
    JAMA; 1983 Mar; 249(12):1565. PubMed ID: 6219234
    [No Abstract]   [Full Text] [Related]  

  • 25. Development of bacterial resistance to the third generation cephalosporins and their clinical use.
    Kolár M; Látal T; Hájek V
    J Chemother; 1999 Aug; 11(4):260-5. PubMed ID: 10465127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.
    Adu A; Armour CL
    Drugs; 1995 Sep; 50(3):423-39. PubMed ID: 8521766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Third-generation cephalosporins: comparative antibacterial activity against routine clinical isolates.
    Corser CA; Day GJ; Humble MW
    N Z Med J; 1982 Jun; 95(710):414-6. PubMed ID: 6810246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Susceptibility of ceftazidime and other cephalosporins to a range of beta-lactamases and their potential as inducing agents.
    Mouton RP; Bongaerts GP; van Gestel MH
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():147-52. PubMed ID: 19802978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cephalosporin-induced hypoprothrombinemia: is the N-methylthiotetrazole side chain the culprit?
    Agnelli G; Del Favero A; Parise P; Guerciolini R; Pasticci B; Nenci GG; Ofosu F
    Antimicrob Agents Chemother; 1986 Jun; 29(6):1108-9. PubMed ID: 3729364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interference of selected second- and third-generation cephalosporins with creatinine determination.
    Guay DR; Meatherall RC; Macaulay PA
    Am J Hosp Pharm; 1983 Mar; 40(3):435-8. PubMed ID: 6846351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Richards DM; Heel RC
    Drugs; 1985 Apr; 29(4):281-329. PubMed ID: 3888599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative activity of seven extended-spectrum cephalosporins against gram-negative bacilli from blood cultures.
    Norris SM; Guenthner SH; Wenzel RP
    J Antimicrob Chemother; 1985 Aug; 16(2):183-8. PubMed ID: 3934124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemorrhage, diarrhea, and superinfection associated with the use of moxalactam.
    Panwalker AP; Rosenfeld J
    J Infect Dis; 1983 Jan; 147(1):171-2. PubMed ID: 6218209
    [No Abstract]   [Full Text] [Related]  

  • 34. Thrombocytopenia possibly caused by structurally related third-generation cephalosporins.
    Hull RL; Brandon D
    DICP; 1991 Feb; 25(2):135-6. PubMed ID: 2058185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized trial of cefepime (BMY-28142) and ceftazidime for the treatment of pneumonia.
    Edelstein H; Chirurgi V; Oster S; Karp R; Cassano K; Aiken S; McCabe R
    J Antimicrob Chemother; 1991 Oct; 28(4):569-75. PubMed ID: 1761451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hemostasis disturbance caused by cephalosporins with an N-methylthiotetrazole side chain. A randomized pilot study].
    Schäfer H; Naber K; Adam D
    Arzneimittelforschung; 1989 Sep; 39(9):1156-62. PubMed ID: 2590268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Laboratory and clinical studies on ceftazidime in the field of pediatrics].
    Kuno K; Yafuso M; Miyachi Y; Nakashima T; Ichihara K; Ueda S
    Jpn J Antibiot; 1984 Mar; 37(3):469-84. PubMed ID: 6376856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coagulopathy associated with the use of moxalactam.
    Pakter RL; Russell TR; Mielke CH; West D
    JAMA; 1982 Sep; 248(9):1100. PubMed ID: 6213792
    [No Abstract]   [Full Text] [Related]  

  • 39. Aspects of clinical trials with ceftazidime worldwide.
    Foord RD
    Am J Med; 1985 Aug; 79(2A):110-3. PubMed ID: 3895913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastrointestinal reactions to cefoperazone.
    Norrby R; Alestig K
    Lancet; 1981 Dec 19-26; 2(8260-61):1417. PubMed ID: 6118780
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.